Plain-English translation of NCT07604324 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This is a first-in-human study testing a new medication called to see if it is safe and how the body handles it. The trial has two parts: first, healthy volunteers receive increasing doses to check for safety, and then people with moderate to severe atopic dermatitis receive the medication to see if it helps their condition. This medication is being tested because current treatments don't work well enough for everyone.
Atopic dermatitis is a chronic skin condition that causes severe itching, redness, and inflammation that can significantly affect quality of life. Many patients do not respond adequately to current treatments, so researchers are testing this new medication to see if it offers a better option.
You likely qualify if…
You likely don't qualify if…
If you qualify for Part 1 (healthy volunteers), you will receive a single dose of the medication or placebo and be monitored for safety over several visits. If you qualify for Part 2 (people with atopic dermatitis), you will receive multiple doses of the medication over time and have regular visits where researchers will assess your skin condition, itching, and any side effects. The study involves blood tests, skin assessments, and detailed safety monitoring throughout your participation.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Japan